In short – not a lot in the short-term. The vote in favour of a 0.3% THC limit by the European Parliament (EP) is only the first step in a long process towards actually putting such a change into effect.
Holiday sales overall mean more to US companies than their UK counterparts, but the novelty of Black Friday means some are embracing a discount period as a means to create new sales, according to a number of companies
Nestlé has taken a baby step into the European cannabidiol market just a year after creating its own CBD line in the US and will now distribute soft gel CBD capsules in the UK through the Pure Encapsulations brand
Our host for today’s podcast is Jon Bruford, a copy editor at CBD-Intel, who will be joined by CBD-Intel market analyst Maria Alejandra Estanga, who analyses the CBD market for European and American countries. In CBD-Intel’s new podcast, Alejandra discusses global CBD markets and their commonalities and differences, analysing each market and its own peculiarities […]
Maria Alejandra Estanga, our market analysts, presented the current status of the topicals market across the most important CBD markets during the Virtual Cannacosmo Health + Beauty Expo on 29st September.
US-based CBD producer Folium Biosciences is looking to tap Asian markets by creating a dedicated stalk extraction line which it believes will meet the strict regulatory requirements of Japan and South Korea
Britain’s newfound enthusiasm for CBD products has joined with the passion for alcohol, with some companies are aiming to capitalise on the trend for “drinking less but drinking better” by launching CBD spirits, especially gin
CBD-Intel managing director, Tim Phillips, discusses the main facts and issues surrounding CBD and Novel Food status in European markets. He presents the key aspects of the delay, the political issues and the impacts released on the European level and the future challenges for the sector.
The trade body for hemp and CBD in Ireland has accused the Irish government of working in silos and said its lack of intra-governmental communication as well as consultation with stakeholders could lead to the end of the industry in the country
Registration in the US FDA National Drug Code (NDC) Directory conveys significant benefits even if the FDA does not specifically approve these items as over-the-counter products, according to a CBD company
It remains unclear where the hemp and CBD investment centre for Asia will develop. History and existing infrastructure would point to Hong Kong, but development there has stalled – and there are other contenders
Enforcement activity against food, drink and dietary supplement products placed on the market containing CBD continues despite the inability of companies to proceed with novel food applications due to the EC’s questions over whether CBD constitutes a narcotic under the 1961 UN Single Convention on Narcotics.
Several major developments have all happened at the same time for novel foods. Perhaps most importantly, one of the European Commission’s departments – the Directorate-General for Health and Food Safety – has said it is holding sending any further non-synthetic CBD applications to the European Food Safety Authority for evaluation until it has determined whether CBD technically falls under the definition of a narcotic according to the 1961 UN Single Convention on Narcotic Drugs.
A strong online presence has been essential to resiliency through the COVID-19 pandemic, but many larger offline retail chains that have also focused on selling through these channels may still see a recovery
CBD companies are in a fairly unique place in that they cannot use their primary function – health and wellness – to advertise their brands. And this is not without reason – as shown by the numerous instances of scurrilous companies making outlandish claims about CBD and cancer, Alzheimer’s and other diseases where a “miracle cure” is seemingly often the last chance of the desperate.
In a case that illustrates difficulties a number of CBD businesses have encountered in reaching their target market, a CBD company in the US is suing a TV advertising firm, alleging deceptive trade practices and breach of contract
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Do the Novel Food regulations in Europe affect your business?
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.